ArticlemedRxiv : the preprint server for health sciences2025
Indirect Benefits of Seasonal Malaria Chemoprevention for Non-Malarial Pediatric Infections and Routine Antibiotic Use in Real-World Programmatic Settings: A Pre-Post Study Using Positive and Negative Controls.
Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
15 authors.
Funding
Abstract
Objective: To assess the benefits of Seasonal Malaria Chemoprevention (SMC), the monthly administration of sulfadoxine-pyrimethamine and amodiaquine during the high malaria season, beyond malaria prevention in real-world program settings. Methods: We conducted a pre-post comparison of non-malarial diagnoses (pneumonia, diarrhea, acute malnutrition) and antibiotic prescription rates during SMC administration weeks versus a three-week post-intervention period in rural Burkina Faso. Data came from clinic surveillance at 51 health facilities, a population-based census, and National Malaria Control Program data on SMC timing. Poisson regression models with person-weeks as an offset and standard errors clustered by health post estimated changes in rates. Interaction terms assessed variation across SMC cycles. Positive (malaria diagnoses, antimalarial prescriptions) and negative (injury) control outcomes were used to evaluate potential unmeasured confounding. Results: Compared to administration weeks, modest declines were observed in pneumonia, diarrhea, and acute malnutrition diagnoses, as well as in antibiotic prescription rates during the post-SMC period. Absolute reductions were 0.7 (95% CI: 0.3-1.0), 0.2 (95% CI: 0.1-0.4), 0.05 (95% CI: 0.001-0.09), and 0.90 (95% CI: 0.4-1.4) per 1,000 person-weeks, respectively. Positive control outcomes also declined, with malaria diagnoses and antimalarial prescriptions decreasing by 3.7 (95% CI: 2.6-4.8) and 3.6 (95% CI: 2.5-4.7) per 1,000 person-weeks. Injury rates (negative control) remained stable (0.02; 95% CI: -0.03 to 0.07). Reductions varied across SMC cycles and were most pronounced following the final round. Conclusion: SMC may have additional benefits beyond malaria prevention, including reductions in common pediatric infections and subsequent routine antibiotic use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.